英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • nab -Paclitaxel dose and schedule in breast cancer - PubMed Central (PMC)
    nab-Paclitaxel is approved for the treatment of metastatic breast cancer on an every-3-week schedule based on positive findings from a pivotal phase III trial in which nab-paclitaxel 260 mg m2 every 3 weeks was superior to solvent-based paclitaxel
  • Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High . . .
    Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was approved in 2005 for the treatment of metastatic breast cancer, primarily on the basis of a phase III trial that compared every-3-week administration of nab-paclitaxel 260 mg m 2 as a 30-minute infusion with standard paclitaxel (s-paclitaxel) 175 mg m 2 as a 3-hour infusion
  • nab-PACLitaxel Weekly Monotherapy–28 day - HSE. ie
    nab-PACLitaxel is administered on days 1, 8 and 15 of a 28 day treatment cycle as an alternative to weekly PACLItaxel for patients who are unable to receive standard PACLitaxel formulation for the above indication Treatment should continue until disease progression or unacceptable toxicity develops
  • Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel . . .
    16-week neoadjuvant nab-paclitaxel induces higher pCR than sb-paclitaxel–epirubicin cyclophosphamide in high-risk HR+ HER2− breast cancer First prospective phase III trial showed that higher RS is predictive for pCR Associations of higher RS and ET non-response with pCR are moderated by menopausal status (and or ET agent used)
  • Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
    We conducted a study to compare the efficacies of two aspects of current adjuvant chemotherapy in patients with axillary lymph node–positive or high-risk, lymph node–negative breast cancer:
  • nab-Paclitaxel dose and schedule in breast cancer - BioMed Central
    In general, weekly dosing during the first 3 of 4 weeks appears to achieve the best clinical benefit in both the metastatic and early-stage settings
  • Weekly nab-Paclitaxel in Metastatic Breast Cancer - PubMed
    During an advisory board meeting, a group of 8 German breast cancer experts reviewed the clinical data of nab-paclitaxel in MBC and discussed how nab-paclitaxel could be used in clinical practice on the basis of the current data
  • Weekly nab -Paclitaxel in Metastatic Breast Cancer - PubMed Central (PMC)
    The combination of weekly nab-paclitaxel and trastuzumab as first-line treatment was evaluated in a phase II study with 72 patients (50 HER2-negative and 22 HER2-positive) with locally advanced breast cancer or MBC Nab-paclitaxel was administered at 125 mg m 2 on days 1 8 15 of a 28-day cycle plus concurrent trastuzumab (loading dose 4 mg kg


















中文字典-英文字典  2005-2009